Revolution Medicines Inc (RVMD)
Healthcare
Biotechnology
187.50 $
-2.4%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Revolution Medicines Inc (RVMD)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 91.3% of the shares are freely tradable; institutional investors hold 95.7%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
95.7%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
1.9%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
91.3%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
7.0%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
213Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Farallon Capital Management, L.L.C. | 6.40 | 13,604,796 | -6.7 | 03/31/2026 |
| BlackRock Inc | 5.27 | 11,212,706 | +25.6 | 03/31/2026 |
| HHG PLC | 4.59 | 9,766,496 | -20.6 | 03/31/2026 |
| Baker Bros Advisors LP | 4.49 | 9,555,357 | +1.1 | 03/31/2026 |
| FMR Inc | 3.98 | 8,464,314 | -1.4 | 03/31/2026 |
| Vanguard Capital Management, LLC | 3.93 | 8,362,284 | +0.0 | 03/31/2026 |
| Nextech Invest, Ltd. | 3.58 | 7,601,087 | +0.0 | 03/31/2026 |
| Vanguard Portfolio Management, LLC | 3.53 | 7,502,623 | +0.0 | 03/31/2026 |
| Paradigm Biocapital Advisors LP | 3.13 | 6,655,703 | +0.2 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Morn Total Stk Mkt Idx Investor | 3.02 | 6,413,554 | +1.6 | 06/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.